ArticleNeurogastroenterology and motility2026
National Medical Expenditures Associated With Pediatric Disorders of Gut-Brain Interaction in the United States.
Article in Neurogastroenterology and motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Composite fiber remodels gut microbiota and shows a trend of alleviating dyspepsia in adolescents with functional dyspepsia: a 16S rRNA pilot study.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLimited research has evaluated national medical expenditures associated with pediatric disorders of gut-brain interaction (DGBI), despite the high prevalence of these disorders in children and their association with reduced quality of life.
methodsWe used data from the 2017-2022 Medical Expenditure Panel Survey (MEPS) to estimate the individual- and national-level outpatient, office-based, prescribed medication, emergency room, inpatient, and other medical expenditures, and overall expenditures associated with pediatric DGBI. Pediatric DGBI included International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10) codes associated with irritable bowel syndrome, functional dyspepsia, and other functional intestinal disorders (including constipation) among 40,067 individuals ≤ 18 years receiving medical care in the United States. KEY
resultsAfter controlling for predisposing factors, enabling resources, and co-morbid medical conditions, total per patient annual medical expenditures were $5217 (in 2022 dollars) for pediatric patients with DGBI-an estimate that was $2587 greater than the estimated medical expenditures for children without DGBI. Incremental spending from DGBI patients versus patients without DGBI was highest for outpatient visits followed by office-based visits, prescribed medications, and emergency room visits. Total annual medical expenditures for pediatric patients with DGBI were estimated at $2.08 billion. CONCLUSIONS AND INFERENCES: The results illuminate the significant national medical expenditures associated with pediatric DGBI, suggesting the potential importance of early detection and effective treatment for pediatric DGBI and the need for future research to improve assessment and evidence-based treatment for pediatric DGBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.